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Curcumin (diferuloymethane; CUR) is a yellow pigment used in traditional medicine
throughout history for its anti-inflammatory activity. In the last years, the scientific
research has demonstrated that CUR effects are related to the modulation of crucial
molecular targets, related to several pathologies including cancer, arthritis, diabetes,
Crohn’s disease. In this paper, two formulations of microencapsulated CUR obtained
by coevaporation with polymethacrylate polymers (Eudragit©R Retard) were investigated
in vitro, ex vivo, and in vivo, and results were compared by laser confocal microscopy
analysis. The permeation of microencapsulated CUR through CaCo-2 monolayers
was evaluated in vitro. The mucoadhesion and bioadhesion of the CUR-loaded
microparticles were evaluated in vitro, using E12 and CaCo-2 human intestinal cells,
and ex vivo, by means of excised rat intestinal mucosa. After oral administration to
rats, microencapsulated CUR showed a sevenfold increase of bioavailability in respect
to the neat drug, with a concomitant reduction of the Tmax and a five-fold plasma
concentration peak increase.
Keywords: Eudragit R© Retard, microparticles, mucoadhesion, CaCo-2 cells, E12 cells, CLSM
INTRODUCTION
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; CUR] is the most
active component of turmeric (Curcuma longa), a perennial herb belonging to the ginger family.
It has been used in traditional Indian medicine for about 6000 years to treat wounds, rheumatism
and inflammatory diseases (Corson and Crews, 2007; Jurenka, 2009; Leonti and Casu, 2013) but,
in the last 50 years, scientific research demonstrated that CUR possesses additional activities such
as antioxidant (Soudamini et al., 1992), anti-inflammatory (Abe et al., 1999), anti-atherosclerotic,
anti-angiogenesis, and anti-carcinogenic ones (Kunnumakkara et al., 2008). CUR promotes wound
healing and muscle regeneration (Panchatcharam et al., 2006), prevents liver injury and kidney
toxicity, and exerts medicinal benefits against psoriasis, diabetes, multiple sclerosis, Alzheimer
disease, HIV, septic shock, cardiovascular diseases, lung fibrosis, arthritis, and inflammatory bowel
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disease (IBD), among the most described pathologies (Mecocci
et al., 2014; Vecchi Brumatti et al., 2014; Conti et al., 2016).
Moreover, CUR demonstrated to successfully inhibit almost
every major stage of carcinogenesis, including metastasis (Anand
et al., 2008; Liu et al., 2009; Shu et al., 2011).
These wide range of activities are primarily due to the capacity
of CUR to modulate various signaling pathways, such as COX-
2, MMPs, glutathione, protein kinase C, ATPase, nuclear NF-kb,
AP-1, P-gp, MRP-1, MRP-2, ErbB2, α1-acid glycoprotein, Cyclin
D1, and others (Anand et al., 2008; Kunnumakkara et al., 2008).
Most importantly, many preclinical and clinical studies have
confirmed that CUR is significantly non-toxic even at very high
doses (Mohanty et al., 2012).
Unfortunately, this compound evidences different problems
for its application, such as low-aqueous solubility, rapid systemic
clearance, inadequate tissue absorption and degradation at
alkaline pH values. As a consequence, its oral bioavailability is
extremely poor and CUR can be classified as a class IV compound
in the BCS system (Wahlang et al., 2011). Furthermore, the drug
is rapidly photodegraded by light, also limiting its clinical use
(Cañamares et al., 2006; Kumavat et al., 2016). To overcome these
drawbacks, different strategies of micro- and nano-encapsulation
of CUR in lipid and polymeric matrices have been investigated
(Anand et al., 2007; Bansal et al., 2011; Mohanty et al., 2012;
Yallapu et al., 2012, 2014; Lee et al., 2014; Shome et al., 2016;
Szymusiak et al., 2016).
Recently, we developed CUR-loaded microparticles made
up of Eudragit R© Retard copolymers, and we observed that
this approach, although was not effective in improving the
solubility of CUR in simulated gastric and intestinal fluids, was
instead able to protect the drug from UV light-induced chemical
degradation (Pecora et al., 2016). Eudragit R© Retard resins
are poly(ethylacrylate, methyl-methacrylate and chlorotrimethyl-
ammonioethyl methacrylate) copolymers, bearing 4.5−6.8% and
8.8−12% quaternary ammonium groups, respectively in the
commercial resins called Eudragit RS100 (ERS) and RL100 (ERL).
These materials are commonly employed for pH-independent
coating of solid oral drug dosage forms; however, since they
are insoluble in water at physiological pH values and undergo
a certain degree of swelling (Bodmeier and Chen, 1989), they
may be suitable for the dispersion and controlled oral delivery
of bioactives (Barkai et al., 1990; Pignatello et al., 2001, 2002a,b;
Bucolo et al., 2004; Das et al., 2010; Cortesi et al., 2012; Hoobakht
et al., 2013).
The bioadhesion is a fundamental prerequisite to be
investigated when a drug delivery system is orally administered
and it can involve the formation of adhesive bonds between
a compound or a material and biological tissues. When
the adherent substrate is a mucosal surface, bioadhesion
is specifically referred to as mucoadhesion (Shaikh et al.,
2011). A common strategy to improve the oral bioavailability
of drugs is to use polymers with bioadhesive/mucoadhesive
properties, because they may increase the residence time in the
gastrointestinal tract.
The aim of this research was to evaluate the in vitro, ex vivo,
and in vivo bioadhesion properties of two novel formulations
of CUR-loaded ERL/ERS microparticles, characterized by a
different drug-to-polymer ratio (DPR), namely 1:5 or 1:10. The
bioadhesion of CUR microparticles was investigated by confocal
laser scanning microscopy (CLSM) with respect to the free drug
on CaCo-2 cells and the permeation profile of the drug was
evaluated by using a monolayer of the same cell line. Moreover,
HT29MTXE12 (E12) cell line, a goblet cell-like subclone of the
human colon carcinoma HT29 cell line, which is able to secrete an
adherent mucus layer (Navabi et al., 2013), was used to evaluate
the microparticle mucoadhesion. The latter property was also
investigated by an ex vivo model of rat gut sac. Finally, the in vivo
bioavailability of CUR following the oral administration of the
drug as free form or in the microparticles was assessed.
MATERIALS AND METHODS
Materials
CUR (Curcuma longa rhizome dry extract; total curcuminoids
95% min.) was produced by Vivatis Pharma GmbH (Hamburg,
Germany) and was kindly gifted by Labomar srl (Istrana, Italy);
ERL and ERS resins (Evonik Rohm GmbH, Darmstadt,
Germany) were kindly provided by Rofarma Italia srl
(Gaggiano, Italy). CaCo-2 epithelial cells were obtained
from the Zooprophylactic Institute of Lombardia and Emilia
Romagna; E12 cells were purchased from Sigma-Aldrich Chimica
srl (Milan, Italy). HPLC solvents were purchased from VWR PBI
International (Milan, Italy); all other materials and solvents used
throughout this investigation were of analytical grade (Carlo
Erba, Milan, Italy).
Production of CUR Microparticles
The Eudragit R© resin blend (ERL/ERS, 30:70, w/w) (2 mg total)
was dissolved in 20 ml of ethanol by overnight mechanical
stirring at room temperature. The amount of drug required
to obtain the chosen DPR weight ratios (1:5 or 1:10, for
batches CEM1 and CEM2, respectively) was dissolved in 10 ml
acetone and added to the polymer solution. The mixture was
then slowly dropped, within 60 min, through a glass burette
into 50 ml distilled water containing 0.02% (w/v) Tween R© 80,
under mechanical stirring at 150 rpm and room temperature,
to produce the microparticles. The suspension was left stirring
at room temperature for about 24 h to allow the evaporation of
the solvents; the final polymer concentration was 4% (w/v). The
product was then frozen at −20◦C for 12−16 h and lyophilized
for 24 h (Edward Modulyo).
The solid samples were finally passed through European
Pharmacopoeia standard metallic sieves using a vibratory
apparatus (Giuliani Tecnologie srl, Turin, Italy), to collect the
microparticle sieve fractions between 420 and 125 µm (40 to 120
mesh).
Details of physico-chemical characterization of the obtained
microparticles have been previously described (Pecora et al.,
2016).
Cell Cultures
E12 cells and Caco-2 cells were cultured in Dulbecco’s Modified
Eagles Medium (DMEM) at 37◦C (5% CO2). Cells were seeded
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using D-MEM medium with glutamine, penicillin (100 UI/mL),
streptomycin (100 µg/mL), amphotericin B (250 µg/mL), and
FBS (10% v/v).
Permeation Experiments through
CaCo-2 Cells
In vitro permeation studies were performed using CaCo-2
epithelial cells used between passage 21 and 38. They were
seeded at a density of 104/cm2 into SnapwellsTM (1 cm2,
0.4 µm pore size; Costar Corporation, Milan, Italy). The
growth media was replaced every day. Confluent cell monolayers
were obtained 18–22 days after seeding. The confluence
was demonstrated by means of the trans-epithelial electrical
resistance (TEER) measured with a voltmeter (Millicell ERS).
The measured TEER was between 500 and 600 cm. Permeation
experiments were performed by means of Franz type diffusion
cells, putting the SnapwellsTM containing the CaCo-2 cells
monolayer on the donor compartment. An aliquot of 200 µl
of a suspension of neat CUR in PBS (pH 7.4) (1 mg/ml,
corresponding to 2.7 mM) or of each formulation (CEM1
or CEM2) containing an equivalent amount of drug was
applied to the monolayer. The acceptor phase was PBS (pH
7.4) containing 0.5% (w/v) hydroxypropyl-β-cyclodextrin (HP-
β-Cyd) as a solubilizing agent to facilitate CUR permeation.
Samples from the receiving solution were withdrawn at different
times during the experimental period (6 h); the sample volumes
were immediately replaced with the same amounts of fresh HP-
β-Cyd solution. At the end of the experiments the TEER was
re-measured to check the cell monolayer integrity. All samples
were analyzed by HPLC to determine the concentration of CUR.
The obtained values were corrected for the dilution used during
sampling.
Confocal Laser Scanning Microscopy
(CLSM)
The interaction between the CaCo-2 cells and CUR formulations
was also evaluated by CLSM studies. Briefly, the cells were
placed in 6-well culture plates (4 × 105 cells/ml) containing
a sterile glass slide. Successively, the cells were treated with
CUR (100 µM) as the free drug or loaded microparticles
and incubated for 6 and 24 h. After incubation, each well
was washed three times with PBS to remove the excess of
drug/formulations and cells were fixed on the sterile glass as
previously described (Cosco et al., 2015). The CLSM analysis
was carried out using a laser scanning confocal microscopy
(CLSM) Leika TCS SP2 MP at λexc = 440−470 nm and
λem = 480−519 nm for CUR and at λexc = 405 nm, and
λem = 460 nm for Hoechst probe used with the aim of evidencing
the nuclei.
A scan resolution up to 1024 × 1024 pixels with an Ar/Kr
laser beam of 75 mW, equipped with a 488/405 analyzer
filter, was used for experimental investigations. Samples were
recorded by a macro developer software package having multi-
dimensional series acquisition and direct access digital control
knobs. An immersion oil lens 63× was used, with a 2×
magnification.
HPLC Determination
The HPLC analysis was performed according to literature
(Tønnesen et al., 1986; Pecora et al., 2016) on a Hewlett-
Packard 1100 chromatograph equipped with on-line diode array
detector (DAD) and a Kontron SFM fluorescence detector
(FLD). The freeze-dried samples were redissolved in 1 ml
HPLC-grade methanol and injected into a 20-µl loop combined
with an analytical C18 Chrompack Inertsil ODS-2 column
(Varian, 4.6 mm × 250 mm, 5 µm) shielded by a pre-column
(4.6 mm × 4.5 mm). Chromatograms were generally recorded
using FLD (λexc 422 nm, λem 557 nm) and DAD (absorbance
centered at 420 nm). An isocratic flow rate of 1 ml/min of
methanol/water (96:4, v/v) was employed. A freshly prepared
CUR standard in methanol (0.1 mg/ml) was used to create a
calibration curve (linear in the range 1−8 µg/ml; r2 = 0.988).
In Vitro Evaluation of Bioadhesion and
Mucoadhesion
CaCo-2 and E12 monolayers were rinsed with HEPES-buffered
DMEM and equilibrated in the same medium at 37◦C for 60 min.
The cells were seeded at a density of 2 × 104 cells/filter on onto
TranswellsTM polycarbonate membrane inserts (1 cm2, 0.4 µm
pore size: Costar Corporation, Milan, Italy). Confluence was
reached in 24 days. At the end of this period, 0.5 ml of CEM1
and CEM2, or a suspension of CUR (1 mg/ml) in PBS (pH
7.4) were added to the apical side of the monolayer at two drug
concentrations (0.1 or 0.01 mg/ml). Monolayers were incubated
at 37◦C in a Titramax 1000 shaking incubator for 60 min at
100 rpm. The formulations were then aspired and monolayers
were washed three times with the incubation buffer. CUR was
quantified by HPLC and the results were expressed as percentage
of the applied dose.
Ex Vivo Mucoadhesion Assay
Male Wistar rats (290–340 g) were purchased from Harlan, Italy
(Correzzana, Milan, Italy). Animal experiments followed the
main procedure outlined by the local Ethics Committee, Italian
law and the accepted international standards for biomedical
research. Care and handling of the animals followed the EEC
Council Directive 86/209, recognized and adopted by Italian
Government (D.M. 95/2003-D). Rats were fasted overnight
before euthanasia by cervical dislocation. The intestine was
removed after the incision, and the jejunum was cut in 5-cm
pieces, everted, and one of its ends sutured; the resulting sac was
filled with saline. The sacs were introduced into tubes containing
the formulation under analysis (0.1 mg/ml) and incubated under
stirring for 60 min. The sacs were then removed and washed
sequentially four times with a total of 5 ml of medium; the washes
were pooled and assayed by HPLC. Results were expressed as the
percentage of the applied CUR dose.
Oral Bioavailability
Male Wistar rats (290–340 g) were housed in a temperature-
(23 ± 1◦C) and light-controlled room (12 h light/dark cycle).
They were allowed ad libitum access to food and water and
commercial for 7 days. Rats were randomly divided into three
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groups of eight animals each. The control group was given
neat CUR as a suspension in PBS (pH 7.4) (at 1 mg/ml drug
concentration). The second and third groups were treated with
CEM1 or CEM2, respectively. The CUR dose in all groups
was fixed at 100 mg CUR/kg b.w. All the formulations were
orally administered by oral gavage by mean of flexible plastic
tubes of the length of 5 cm. At pre-determined interval (0, 30,
60, 90, 120, 180, 240, 300, and 360 min) after administration,
blood was harvested from the abdominal Vena Cava of rats
under light anesthesia (diethyl ether) and placed into heparinized
tubes to prevent clotting. Plasma was immediately prepared by
centrifugation at 1000 × g for 15 min at 4◦C and stored at
−80◦C until analysis. Plasma (200 µL) was mixed with 200 µL of
0.1 M sodium phosphate buffer (pH 6.8) containing 0.1% EDTA,
200 µL of distilled water, and 600 µL of methanol. The mixture
was vortexed for 3 min and, after the addition of 4 mL of hexane,
was shaken vigorously and centrifuged at 1000 × g for 10 min at
4◦C. The hexane layer was discarded and 1.2 mL of distilled water
and 3 mL of ethyl acetate were added to the mixture (aqueous-
methanol layer). This was shaken vigorously and centrifuged at
1000 x g for 15 min at 4◦C, and the ethyl acetate layer was finally
collected. This ethyl acetate extraction was repeated four times.
The combined extraction phases were evaporated to dryness in
vacuo and the residue was dissolved in 100 µL of methanol to be
analyzed for CUR content by HPLC, as described above.
Pharmacokinetic calculations were carried out using
WinNonlin Professional, version 5.3 (Tharsight, Mountain View,
CA, USA).
Statistical Analysis
Experimental data were analyzed by one-way analysis of variance.
A posteriori Bonferroni t-test was done to check the analysis of
variance test. A P-value < 0.05 was considered to be statistically
significant. Values are reported as the mean± SD.
RESULTS AND DISCUSSION
Curcumin (diferuloymethane) is a natural compound, possessing
a potent antioxidant activity, and other biologically interesting
effects (Perrone et al., 2015), but whose therapeutic use is
strongly limited by the very low solubility and oral bioavailability
(it belongs to class IV of the Biopharmaceutical Classification
System, BCS), along with a rapid metabolism into inactive
metabolites and rapid clearance from the body (Anand et al.,
2007). Furthermore, at neutral or basic (i.e., intestinal) pH values,
CUR becomes rapidly inactivated (Wang et al., 1997).
Daily doses up to several grams are then usually recommended
for pure CUR or turmeric in order to reach active serum
concentrations of the active compound. Due to the large
therapeutic and commercial (nutraceutical) interest toward CUR,
various strategies have been exploited and sometime marketed
to make CUR more soluble and absorbable through the gut:
along with the complete range of lipid- and polymer-based
micro- and nanocarriers (micelles, liposomes, nanoparticles,
SLN, etc.) (Dutta and Ikiki, 2013; Kurita and Makino, 2013;
Prasad et al., 2014; Shome et al., 2016; Szymusiak et al., 2016),
also chemically-driven solutions have been attempted, such as
phytosomes (Kidd, 2009), molecular dispersions in hydrophilic
polymers or gels, blending with adjuvants, up to chemical
modifications to the molecule of the drug (Sehgal et al., 2011).
Evidence of in vivo enhanced bioavailability in human subjects
for a CUR nanoparticle formulation (Theracurmin R© ) has been
recently reported (Kanai et al., 2012). Another recently patented
technology (EnterosomaTM, Labomar srl) has been exploited to
enhance gut absorption and systemic bioavailability of CUR.
This technology is based on a gastro-resistant tablet whose core
contains a combination of chitosan salified with N-acetylcysteine
(NAC) and a polysorbate, that work in synergy to reduce the
intestinal and hepatic degradation of naturally-derived active
ingredients (Labomar, 2013).
In this research, we evaluated in different biological models
two formulations of CUR microencapsulated with a 30:70
ERL/ERS blend, and characterized by a 1:5 (batch CEM1) or
1:10 DPR value (batch CEM2). They correspond to samples D42
and D43 in the paper describing their preparation (Pecora et al.,
2016).
The intestinal drug absorption of a drug depends on various
factors, such as the intrinsic stability of the compound in the
intestinal lumen, the metabolic stability towards the enzymes
present within the gut wall/mucosa, the presence of transporters,
when they are involved in the absorption or expulsion of the
considered drug molecules.
Drug permeability across the epithelial mucosa and the gastro-
intestinal transit time of the dosage form can be considered
among the most relevant of these factors. In the case of CUR, its
low permeability has been justified by considering an extensive
intestinal first-pass metabolism and accumulation inside gut wall
cells (Wahlang et al., 2011). Thus, based on its poor aqueous
solubility and intestinal permeability, CUR is usually classified as
a BCS Class IV molecule.
Therefore, to assess the performance of the proposed
microparticle formulations, the permeation of loaded CUR
through a CaCo-2 cell monolayer was tested in vitro, along
with the microparticle mucoadhesion features; the latter property
was also evaluated ex vivo in an inverted rat gut assay. In vivo
bioavailability of CUR microparticles was finally evaluated in rats.
Permeation Experiments Through
CaCo-2 Monolayers
An important parameter to be considered for a drug administered
orally is the absorption through the intestinal mucosa. An
interesting, preliminary test that may be predictive is the
evaluation of the permeation through a monolayer of CaCo-
2 cells. These cells in fact possess morphological characteristics
proper of small intestine cells, such as tight intercellular junctions
and microvilli. Moreover, they express intestinal enzymes
(aminopeptidases, esterases, sulfatases, and cytochrome P450
enzymes) and transporters (e.g., bile acid carrier, large neutral
amino acid carrier, biotin carrier, monocarboxylic acid carrier,
PEPT1, and p-glycoprotein) (Ng and Borchardt, 1993).
The microparticles containing CUR and free CUR were thus
tested on CaCo-2 monolayers. As reported in Figure 1, both
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FIGURE 1 | Permeation profiles of neat or microencapsulated CUR
(CEM-1 and CEM-2 formulations) through CaCo-2 cells monolayers.
the examined microparticle batches showed an enhancement of
CUR permeation compared to the neat drug. At the end of the
experiment, CEM1 and CEM2 microparticles showed a CUR
permeation of 31.2 and 28.5%, respectively, compared to 6.2%
for the neat drug, corresponding to 5- and 4.6-fold increase,
respectively. No significant variation was observed between the
two microparticles formulations, which differ for the weight ratio
between CUR and the copolymers (DPR value).
In Vitro Evaluation of Bioadhesion and
Mucoadhesion
To improve the permeability of a drug following oral
administration, a common strategy is to prolong its residence
time using a mucoadhesive carrier, that would increase the
gastro-intestinal tract residence time and finally lead to an
improvement of drug oral bioavailability.
To assess the bioadhesive properties of ERL/ERS
microparticles, in vitro cell culture models of human intestinal
epithelium were used. CaCo-2 cells, when cultured onto a
suitable membrane, spontaneously differentiate into monolayers
of polarized enterocytes, connected by tight junction; these cells
lack mucus-secreting goblet cells, therefore they represent a
useful model to evaluate the bioadhesive properties of a drug
formulation.
FIGURE 2 | Experimental results from bioadhesion studies. In vitro (A and B) and ex vivo (C) mucoadhesion assay of neat CUR or microencapsulated in
CEM-1 and CEM-2 formulations. All samples were assayed at two drug concentrations (0.1 or 0.01 mg/ml). Values are the mean (SE) of three to four experiments.
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In our experiments, both CEM1 and CEM2 demonstrated a
good bioadhesion with the cellular support. In fact, a significant
increase of the amount of CUR present on the surface of CaCo-
2 monolayer was registered (about 20%), whereas the neat CUR
gave a residual amount of less than 1% of the applied dose. Also
in this case, no significant difference was observed between two
different microparticle formulations and the two different tested
dilutions of each microparticle suspension (Figure 2A).
Confocal laser scanning microscopy experiments confirmed
this trend: namely, CEM1 evidenced a stronger interaction with
CaCo-2 cells with respect to the free form of the active compound
after 6 h incubation. In fact, in Figure 3, it is possible to
observe a more evident fluorescence of cells when they were
incubated with the microparticles containing the drug, thus
confirming the bioadhesive properties of these systems. This
thesis was confirmed by the investigation of the interaction rate
between CUR microparticles and CaCo-2 after 24 h incubation;
in particular, the fluorescence of cells incubated with neat
CUR was dramatically decreased, probably as a consequence
of metabolism phenomena and cell surface desorption of the
drug, while microparticles allowed to maintain a certain cell
fluorescence (Figure 4). Similar results were obtained with CEM2
FIGURE 3 | Confocal laser scanning microscopy micrographs of CaCo-2 cells treated with free CUR or CEM1 microparticles after 6 h incubation:
CUR filter (A,D), Hoechst filter (B,E), merge (C,F).
FIGURE 4 | Confocal laser scanning microscopy micrographs of CaCo-2 cells treated with free CUR or CEM1 microparticles after 24 h incubation:
CUR filter (A,D), Hoechst filter (B,E), merge (C,F).
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(data not shown), and the described cell interaction profiles are
in very good agreement with the experimental work performed
by Wahlang et al. (2011), who demonstrated that CUR is poorly
permeable across CaCo-2 cells, due to its chemical and biological
degradation.
Even more clear was the difference in the in vitro
mucoadhesive capacity of CUR microparticles compared to the
free drug, using a cell line secreting mucin (E12 cells). Monolayers
of E12 cells can develop a mucus gel layer of approximately
150 µm (Navabi et al., 2013). This layer measure corresponds
to that one of living human upper bowel. The above mucus
works like a significant barrier against permeation of lipophilic
compounds; furthermore, this cell line expresses mucins MUC1
e MUC2, that are located in upper bowel and are implicated in
host-pathogen relationships. Thanks to these properties, the E12
cell monolayer cultures represent a suitable in vitro model to
evaluate the degree of polymer and drug carriers mucoadhesion
(Keely et al., 2005).
Using this model, the two tested microparticle formulations
allowed a drug retention of approximately 60 and 40%,
respectively for the microparticles produced using a DPR
value of 1:5 and 1:10, whereas neat CUR did not show any
mucoadhesive capability in the assay conditions (Figure 2B).
Also in this case, no relevant difference between the two tested
drug concentrations was registered.
Ex Vivo Evaluation of Mucoadhesion
To confirm the results obtained with cell models, further
experiments were realized on the same specimens using the
inverted bowel model. Interestingly, the ex vivo assay produced
overlapping results with the in vitro test on E12 cells, in terms
of CUR percentage remained absorbed in the mucus layer
(Figure 2C). These results demonstrated the reliability of these
experimental models (Keely et al., 2005) and confirmed the
mucoadhesive features of Eudragit R© microparticles, although
these polymers are usually not considered bioadhesive materials,
at least at the level of chitosan or alginates. Our experimental
data showed that these micronized resins ensure an efficient
entrapment inside the bowel epithelial cells mucus layer and also
an interaction with mucin non-secreting cells (CaCo-2).
These findings support their potential role as biomaterials to
obtain DDS suitable for an efficient controlled oral drug release
(Pignatello et al., 1997, 2002a,b).
Oral Bioavailability
The mean CUR plasma concentration–time profiles after oral
gavages of 100 mg/kg b.w. of CUR as an aqueous suspension or
CUR-loaded microparticles CEM1 and CEM2 are expressed in
Figure 5, along with the relevant pharmacokinetic parameters.
After oral administration, neat CUR is characterized by
a relatively fast absorption, after which the drug plasma
concentration decreased rapidly, due to distribution and
metabolization, resulting in a short t1/2 (approximately 1.32 h)
(Reza Kheiri Manjili et al., 2016). In our experiment, CUR was
still detectable in plasma after 6 h, in accordance with literature
data (Reza Kheiri Manjili et al., 2016), although at very low
concentrations.
FIGURE 5 | Plasma concentration/time curves and mean
pharmacokinetic parameters obtained after oral administration
(gastric intubation) to rats of neat or microencapsulated CUR. Each
test group was composed by eight animals.
Conversely, both the tested microparticle formulations
increased by about sevenfold the oral bioavailability of CUR [in
terms of plasma AUC(0−6 h)]. A simultaneous fivefold increase
of the maximum experimental plasma concentration (Cmax) and
reduction of the corresponding peak time (Tmax) from 120 to
90 min were registered (Figure 5). In particular, the increase
of Cmax obtained after the oral administration of microparticles
was not far from the improvement recently registered upon
multiple oral administration of CUR-loaded polymeric nano-
sized micelles (Reza Kheiri Manjili et al., 2016). Most noteworthy,
CUR plasma levels after the administration of microparticles
remained at values just below the Tmax (400−450 µg/ml) for the
entire duration of the experiment (6 h) (Figure 5), indicating a
sustained release of the drug from the polymeric carrier and a
prolonged gastro-intestinal absorption.
From a technological point of view, no significant difference
between the two tested microparticle batches were observed. This
suggests that the encapsulation of CUR within these polymeric
matrices allowed similar features in vivo, in terms of drug release
and adsorption, regardless from the drug and copolymers weight
ratio and composition.
To correctly appraise these experimental data, it must be
considered that microencapsulation of CUR in the ERL/ERS
matrix had shown to induce to a micronization or partial
amorphization of CUR, as suggested by solid-state analysis
(Pecora et al., 2016). Such a physico-chemical change could have
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led to an increase of gastro-intestinal adsorption of the drug.
More specifically, by considering the registered Tmax values, it
can be supposed that a large part of the drug was released and
absorbed at the level of stomach.
From the in vivo experimental results, the higher Cmax and
larger AUC obtained indicated that the microparticles can sustain
the release and absorption of CUR, prolong the drug transit time,
prevent a rapid metabolism and inactivation of the entire dose of
given drug, and thus enhance its bioavailability.
CONCLUSION
Enhancement of the oral absorption profile and bioavailability
of CUR is highly required to convey this promising active
compound in the near future to the vanguard of therapeutic
agents for clinical treatment of human diseases.
Different technological and chemical strategies have been until
recent proposed to make CUR more water soluble and absorbable
in the gastro-intestinal tract. Among the possible tools, polymer-
based microencapsulation shows some useful features, in terms of
costs, stability, easy industrial production and scaling-up, as well
as regulatory acceptance.
In this study we have tested with different in vitro, ex vivo, and
in vivo models two Eudragit R© Retard microparticle formulations
containing CUR, which had previously shown interesting
technological characteristics and the ability of protecting this
drug from photodegradation (Pecora et al., 2016). Microparticles
showed good muco- and bioadhesive properties, which reflected
into an improved in vivo oral bioavailability of CUR, ensuring
higher plasma concentrations of the drug for a longer time,
than those measured after the administration of the neat drug,
and thus advocating a prolonged clinical significance of this
drug.
Confocal laser microscopy studies confirmed that
microencapsulation was able to facilitate the interaction of CUR
−which exists in an amorphous or micro-crystalline form within
the polymer matrix− with gut wall cells.
The positive data collected in this study will prompt to further
investigate CUR-loaded Eudragit R© microparticles in different
models of human pathologies, such as inflammatory bowel
disease and colon cancer.
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